Curanex Pharmaceuticals CURX
NASDAQ CURX
$4.21 -0.83 (-16.47%)
As of: Sep 9, 2026 · 3:47 PM EDT

Curanex Pharmaceuticals (CURX) Research & Development (2025 - 2026)

Curanex Pharmaceuticals' (CURX) quarterly Research & Development came in at $2.6 million in Q2 2026, down 13.07% quarter-over-quarter from $3.0 million in Q4 2025.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Curanex Pharmaceuticals (CURX) Research & Development (2025 - 2026) Analysis & Trends

Curanex Pharmaceuticals (CURX) has reported Research & Development for 2 consecutive years, with $2.6 million the latest figure, recorded in Q2 2026.

Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Johnson & Johnson 643.26 Bn 622.50 Bn 17.26 Bn 3.65 Bn
2 AbbVie 443.31 Bn 436.74 Bn 12.70 Bn 2.34 Bn
3 Merck 364.74 Bn 357.60 Bn 12.21 Bn 9.74 Bn
4 Novartis Ag 266.46 Bn 258.77 Bn 11.24 Bn -2.85 Bn
5 Pfizer 158.57 Bn 146.88 Bn 10.94 Bn 2.81 Bn
6 Sanofi 52.33 Bn 44.95 Bn 10.79 Bn -2.60 Bn
7 Revolution Medicines 43.79 Bn 43.79 Bn - 394.92 Mn
8 Incyte 25.23 Bn 20.69 Bn 1.57 Bn 516.95 Mn
9 United Therapeutics 21.67 Bn 19.01 Bn 683.80 Mn 146.30 Mn
10 Curanex Pharmaceuticals 5.97 Mn 3.03 Mn - 2.59 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.59 Mn
Dec 31, 2025 2.98 Mn
Sep 30, 2025 677,474.00